Biosimilars for RA Succeed in Phase III

PARIS (MedPage Today) -- Two antitumor necrosis factor blockers that were biosimilar to the proprietary agents etanercept (Enbrel) and infliximab (Remicade) were equivalent in efficacy to the original biologic formulations in patients with active rheumatoid arthritis, phase III trials demonstrated.
Source: MedPage Today Geriatrics - Category: Geriatrics Source Type: news